Avaxia Biologics Overview
- Year Founded
-
2005
- Status
-
Acquired/Merged
- Employees
-
15
- Latest Deal Type
-
M&A
- Investors
-
1
Avaxia Biologics General Information
Description
Operator of a clinical-stage biopharmaceutical platform intended to develop gut-targeted therapeutics. The company's platform uses a proprietary oral antibody to develop gut-targeted therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis, enabling patients with inflammatory bowel disease, diabetes and obesity to improve treatment.
Contact Information
Website
www.avaxiabiologics.comCorporate Office
- 128 Spring Street
- Suite 620
- Lexington, MA 02421
- United States
Corporate Office
- 128 Spring Street
- Suite 620
- Lexington, MA 02421
- United States
Avaxia Biologics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Merger/Acquisition | 01-Jan-2018 | Completed | Generating Revenue | |||
| 11. Later Stage VC (Series B1) | 21-Jul-2015 | Completed | Generating Revenue | |||
| 10. Grant | 21-Jan-2015 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series B) | 24-May-2013 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A) | 01-Jun-2012 | Completed | Product Development | |||
| 7. Grant | 19-Mar-2012 | Completed | Product Development | |||
| 6. Later Stage VC | 01-Jun-2011 | Completed | Clinical Trials - Phase 1 | |||
| 5. Grant | 10-Mar-2011 | Completed | Clinical Trials - Phase 1 | |||
| 4. Grant | 04-Nov-2010 | $244K | Completed | Clinical Trials - Phase 1 | ||
| 3. Grant | 01-Apr-2010 | $213K | Completed | Clinical Trials - Phase 1 |
Avaxia Biologics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B1 | ||||||||
| Series B | ||||||||
| Series A | 3,000,000 | $0.000100 | 8% | $1.78 | $1.78 | 1x | $1.78 | 20.17% |
Avaxia Biologics Comparisons
Industry
Financing
Details
Avaxia Biologics Competitors (22)
One of Avaxia Biologics’s 22 competitors is Neurona Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Aldeyra Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| OrphoMed | Venture Capital-Backed | San Francisco, CA | ||||
| Phathom Pharmaceuticals | Formerly VC-backed | Florham Park, NJ | ||||
| Brainstorm Cell Therapeutics | Corporation | New York, NY |
Avaxia Biologics Patents
Avaxia Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2012290104-A1 | Bovine polyclonal antibody specific for human tnf | Inactive | 01-Aug-2011 | ||
| CA-2843315-A1 | Bovine polyclonal antibody specific for human tnf | Inactive | 01-Aug-2011 | ||
| EP-2739650-A2 | Bovine polyclonal antibody specific for human tnf | Inactive | 01-Aug-2011 | ||
| EP-2739650-A4 | Bovine polyclonal antibody specific for human tnf | Inactive | 01-Aug-2011 | ||
| WO-2013019889-A2 | Bovine polyclonal antibody specific for human tnf | Inactive | 01-Aug-2011 | C07K16/241 |
Avaxia Biologics Signals
Avaxia Biologics Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AbbVie Ventures | Corporate Venture Capital | Minority | ||
| Ariel Savannah Angel Partners | Angel Group | Minority | ||
| Beacon Angels | Angel Group | Minority | ||
| Beta Fund | Venture Capital | Minority | ||
| Boston Harbor Angels | Angel Group | Minority |
Avaxia Biologics FAQs
-
When was Avaxia Biologics founded?
Avaxia Biologics was founded in 2005.
-
Where is Avaxia Biologics headquartered?
Avaxia Biologics is headquartered in Lexington, MA.
-
What is the size of Avaxia Biologics?
Avaxia Biologics has 15 total employees.
-
What industry is Avaxia Biologics in?
Avaxia Biologics’s primary industry is Drug Delivery.
-
Is Avaxia Biologics a private or public company?
Avaxia Biologics is a Private company.
-
What is Avaxia Biologics’s current revenue?
The current revenue for Avaxia Biologics is .
-
How much funding has Avaxia Biologics raised over time?
Avaxia Biologics has raised $23.7M.
-
Who are Avaxia Biologics’s investors?
AbbVie Ventures, Ariel Savannah Angel Partners, Beacon Angels, Beta Fund, and Boston Harbor Angels are 5 of 16 investors who have invested in Avaxia Biologics.
-
Who are Avaxia Biologics’s competitors?
Neurona Therapeutics, Aldeyra Therapeutics, OrphoMed, Phathom Pharmaceuticals, and Brainstorm Cell Therapeutics are some of the 22 competitors of Avaxia Biologics.
-
When was Avaxia Biologics acquired?
Avaxia Biologics was acquired on 01-Jan-2018.
-
Who acquired Avaxia Biologics?
Avaxia Biologics was acquired by Circle33.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process